Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: Other
Life Threatening? No
Write-up: Information has been received from Sanofi Pasteur MSD (SPM) (MFR control number DK-1577272925-2016008229) on 17-AUG-2016. Case received from a physician via health authority on 15-AUG-2016 under reference number DK-DKMA-WBS-0004235. A 15-year-old female adolescent patient received GARDASIL, batch number Not available, Dose 1 via intramuscular route on 08-OCT-2008, GARDASIL, batch number Not available, Dose 2 via intramuscular route on 10-DEC-2008, GARDASIL, batch number Not available, Dose 3 via intramuscular route on 15-APR-2009. The patient experienced recurrent infection, headache, dizziness, palpitation, nausea, abdominal pain, diarrhea, voiding difficulty, shortness of breath, cognitive disorder involuntary muscle movement, weakness of legs/weakness of arms and exercise tolerance decreased on an unknown date. The patient stated that she experienced the first symptom recurrent infection 1 month after her 3rd vaccination. The other symptoms followed. Before her vaccinations, the patient did tennis, fitness, horse-back riding in total 9 hours a week. The tilt table test showed that the patient did not fulfill the criteria Postural Orthostatic Tachycardia Syndrome. Other vaccinations or medications unknown. The patient''s outcome was reported as not recovered/not resolved for headache, dizziness, palpitation, nausea, abdominal pain, diarrhea, voiding difficulty, shortness of breath, cognitive disorder, involuntary muscle movement, and weakness of legs/weakness of arms. The patient''s outcome was reported as unknown for recurrent infection and exercise tolerance decreased.
Copyright © 2019 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166